|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Comparison between sitagliptin and nateglinide on postprandial lipid levels: The STANDARD study显示文摘AIM: To assess the effects of sitagliptin and nateglinide on lipid metabolism. METHODS: In a parallel group comparative open trial, patients with type 2 diabetes mellitus under treatment at the Japanese Red Cross Medical Center were randomly assigned to receive either sitagliptin (50 mg once daily) or nateglinide (90 mg three times daily before meals). Eligible patients met the following criteria: age ≥ 20 years; hemoglobin A 1c (HbA 1c ) > 6.5% despite diet and exercise; HbA 1c between 6.5% and 8.0%; fasting glucose < 7.77 mmol/L; diet and exercise therapy for more than 3 mo; and ability to read and understand the information for written informed consent. Exclusion criteria were contraindications to sitagliptin, contraindications to nateglinide, pregnancy or possible pregnancy, and severe liver/renal failure. Patients who were considered to be unsuitable by the attending physician for other reasons were also excluded. Blood samples were collected at one and three hours after intake of a test meal. The primary outcome measure was the area under the curve (AUC) of apolipoprotein (Apo) B48 at three hours postprandially. RESULTS: Twenty patients were randomly assigned to the sitagliptin group and sixteen patients were randomized to the nateglinide group. All 36 patients took the medication as directed by the physician in both groups, and they all were analyzed. Apart from antidiabetic drugs, there was no difference between the two groups with respect to the frequency of combined use of lipid-lowering, antihypertensive, and/or antiplatelet drugs. The doses of these medications were maintained during 12 wk of treatment. Detailed dietary advice, together with adequate exercise therapy, was given to the patients so that other factors apart from the two test drugs were similar in the two groups. There were no significant differences of the baseline characteristics between the two groups, except for body mass index (the sitagliptin group: 25.14 ± 3.05 kg/m 2 ; the nateglinide group: 21.39 ± 2.24 kg/m 2 ). Fasting levels of HbA 1c , glycated albumin, 1.5-anhydroglucitol, and blood glucose, as well as the blood glucose levels at one and three hours postprandially, improved in both groups after 12 wk of treatment, and there were no significant differences between the two groups. However, the glucagon level at one hour postprandially (P = 0.040) and the diastolic blood pressure (P<0.01) only showed a significant decrease in the sitagliptin group. In the nateglinide group, there was no significant change in the AUC of Apo B48, the glucagon level at one hour postprandially, the fasting triglyceride level, or the diastolic blood pressure. Body weight was unchanged in both groups. However, the AUC of Apo B48 at three hours postprandially showed a significant decrease in the sitagliptin group from 2.48 ± 0.11 at baseline to 1.94 ± 0.78 g/L per hour after 12 wk (P=0.019). The fasting triglyceride level also decreased significantly in the sitagliptin group (P = 0.035). With regard to lipid-related markers other than Apo B48 and fasting triglycerides, no significant changes were observed with respect to Apo A1, Apo B, or Apo C3 in either group. No adverse events occurred in either group. CONCLUSION: Sitagliptin significantly improves some lipid parameters while having a comparable effect on blood glucose to nateglinide. A large-scale prospective study of sitagliptin therapy is warranted. | Yuichi Kojima Hideyoshi Kaga Shinu Hayashi Toru Kitazawa Yuko Iimura Makoto Ohno Michiyasu Yoshitsugu Mutsunori Fujiwara Toru Hiyoshi | 2013 | World Journal of Diabetes2013，4，1： | 5 |
| 2 | Distribution of HBV genotypes among HBV carriers in Benin:phylogenetic analysis and virological characteristics of HBV genotype E显示文摘AIM: To determine the distribution of Hepatitis B virus (HBV) genotypes in Benin, and to clarify the virological characteristics of the dominant genotype.METHODS: Among 500 blood donors in Benin, 21 HBsAg-positive donors were enrolled in the study. HBV genotypes were determined by enzyme immunoassay and restriction fragment length polymorphism. Complete genome sequences were determined by PCR and direct sequencing.RESULTS: HBV genotype E (HBV/E) was detected in 20/21 (95.2%), and HBV/A in 1/21 (4.8%). From the age-specific prevalence of HBeAg to anti-HBe seroconversion (SC) in 19 HBV/E subjects, SC was estimated to occur frequently in late teens in HBV/E.The comparison of four complete HBV/E genomes from HBeAg-positive subjects in this study and five HBV/E sequences recruited from the database revealed that HBV/E was distributed throughout West Africa with very low genetic divers ity (nucleotide homology 96.7-99.2%).Based on the sequences in the basic core promoter (BCP)to precore region of the nine HBV/E isolates compared to those of the other genotypes, a nucleotide substitution in the BCP, G1757A, was observed in HBV/E.CONCLUSION: HBV/E is predominant in the Republic of Benin, and SC is estimated to occur in late teens in HBV/E. The specific nucleotide substitution G1757A in BCP, which might influence the virological characteristics,is observed in HBV/E. | Kei Fujiwara Yasuhito Tanaka Etsuro Orito Tomoyoshi Ohno Takanobu Kato Kanji Sugihara Izumi Hasegawa Mayumi Sakurai Kiyoaki Ito Atsushi Ozasa Yuko Sakamoto Isao Arita Ahmed El-Gohary Agossou Benoit Sophie I Ogoundele-Akplogan Namiko Yoshihara Ryuzo Ueda Masashi Mizokami | 2005 | World Journal of Gastroenterology2005，11，41： | 3 |
| 3 | Inhibition of TRPC6 Channel Activity Contributes to the Antihypertrophic Effects of Natriuretic Peptides-Guanylyl Cyclase-A Signaling in the Heart显示文摘 | Hideyuki Kinoshita Koichiro Kuwahara Motohiro Nishida Zhong Jian Xianglu Rong Shigeki Kiyonaka Yoshihiro Kuwabara Hitoshi Kurose Ryuji Inoue Yasuo Mori Yuhao Li Yasuaki Nakagawa Satoru Usami Masataka Fujiwara Yuko Yamada Takeya Minami Kenji Ueshima Kazuwa | 2010 | Circulation Research2010，，12： | 2 |
| 4 | A molecular roadmap for induced multi-lineage transdifferentiation of fibroblasts by chemical combinations显示文摘 | Xiaoping Han Hao Yu Daosheng Huang Yang Xu Assieh Saadatpour Xia Li Lengmei Wang Jie Yu Luca Pinello Shujing Lai Mengmeng Jiang Xueying Tian Fen Zhang Yanhong Cen Yuko Fujiwara Wei Zhu Bin Zhou Tianhua Zhou Hongwei Ouyang Jianan Wang Guo-Cheng Yuan Shumin Duan Smart H Orkin Guoji Guo | 2017 | Cell Research2017，27，3： | 2 |
| 5 | Intra-Arterial Infusion Chemotherapy Using Cisplatin With Radiotherapy for Stage III Squamous Cell Carcinoma of the Cervix显示文摘 | Yuko Kaneyasu Nobutaka Nagai Yasushi Nagata Yasutoshi Hashimoto Shintaro Yuki Yuji Murakami Masahiro Kenjo Hideaki Kakizawa Naoyuki Toyota Hisaya Fujiwara Yoshiki Kudo Katsuhide Ito | 2009 | International Journal of Radiation Oncology Biology Physics2009，，2： | 1 |
| 6 | Photo- swiched storage and release of guest molecules in the pore void of eoumarin-modified MCM-41显示文摘 | Nawal Kishor Masahiro Fujiwara Yuko Tanaka | 2003 | Chem Mater2003，15，33： | 1 |
| 7 | Developmental Origin of a Bipotential Myocardial and Smooth Muscle Cell Precursor in the Mammalian Heart显示文摘 | Sean M. Wu Yuko Fujiwara Susan M. Cibulsky David E. Clapham Ching-ling Lien Thomas M. Schultheiss Stuart H. Orkin | 2006 | Cell2006，，6： | 1 |
| 8 | Extracellular proteome of human hepatoma cell, HepG2 analyzed using two-dimensional liquid chromatography coupled with tandem mass spectrometry显示文摘 | Ryo Yamashita Yuko Fujiwara Kohei Ikari Keiko Hamada Asuka Otomo Kazuki Yasuda Mitsuhiko Noda Yasushi Kaburagi | | 0，2007，： | 1 |
| 9 | Intra-Arterial Infusion Chemotherapy Using Cisplatin With Radiotherapy for Stage III Squamous Cell Carcinoma of the Cervix显示文摘 | Yuko Kaneyasu Nobutaka Nagai Yasushi Nagata Yasutoshi Hashimoto Shintaro Yuki Yuji Murakami Masahiro Kenjo Hideaki Kakizawa Naoyuki Toyota Hisaya Fujiwara Yoshiki Kudo Katsuhide Ito | 2009 | International Journal of Radiation Oncology Biology Physics2009，，2： | 1 |
| 10 | FOG-2 , a Cofactor for GATA Transcription Factors, Is Essential for Heart Morphogenesis and Development of Coronary Vessels from Epicardium显示文摘 | Sergei G Tevosian Anne E Deconinck Makoto Tanaka Martina Schinke Silvio H Litovsky Seigo Izumo Yuko Fujiwara Stuart H Orkin | 2000 | Cell2000，，7： | 1 |
| 11 | Naofen, a novel WD40-repeat protein, mediates spontaneous and tumor necrosis factor-induced apoptosis显示文摘 | Guo-Gang Feng Chang Li Lei Huang Koji Tsunekawa Yuko Sato Yoshihiro Fujiwara Tooru Komatsu Takashi Honda Jun-Hua Fan Hidemi Goto Tatsuro Koide Takaaki Hasegawa Naohisa Ishikawa | 2010 | Biochemical and Biophysical Research Communications2010，，1： | 1 |
| 12 | Enhanced expression of naofen in kidney of streptozotocin-induced diabetic rats: possible correlation to apoptosis of tubular epithelial cells显示文摘 | Yuko Sato Guo-Gang Feng Lei Huang Jun-Hua Fan Chang Li Jun An Koji Tsunekawa Shuji Kurokawa Yoshihiro Fujiwara Toru Komatsu Fumio Kondo Naohisa Ishikawa | 2010 | Clinical and Experimental Nephrology2010，，3： | 1 |
| 13 | MicroRNA-21 Integrates Pathogenic Signaling to Control Pulmonary Hypertension: Results of a Network Bioinformatics Approach显示文摘 | Victoria N. Parikh Richard C. Jin Sabrina Rabello Natali Gulbahce Kevin White Andrew Hale Katherine A. Cottrill Rahamthulla S. Shaik Aaron B. Waxman Ying-Yi Zhang Bradley A. Maron Jochen C. Hartner Yuko Fujiwara Stuart H. Orkin Kathleen J. Haley Albert-Lá | 2012 | Circulation2012，，12： | 1 |
| 14 | FOG-2 , a Cofactor for GATA Transcription Factors, Is Essential for Heart Morphogenesis and Development of Coronary Vessels from Epicardium显示文摘 | Sergei G Tevosian Anne E Deconinck Makoto Tanaka Martina Schinke Silvio H Litovsky Seigo Izumo Yuko Fujiwara Stuart H Orkin | 2000 | Cell2000，，7： | 1 |
| 15 | Mitigation of radiation injury by selective stimulation of the LPA 2 receptor显示文摘 | Gy?ngyi N. Kiss Sue-Chin Lee James I. Fells Jianxiong Liu William J. Valentine Yuko Fujiwara Karin Emmons Thompson Charles R. Yates Balázs Sümegi Gabor Tigyi | 2013 | BBA - Molecular and Cell Biology of Lipids2013，，1： | 1 |
| 16 | Helicobacter cinaedi bacteremia with cellulitis after ABO-incompatible living-donor liver transplantation: Case report显示文摘Helicobacter cinaedi(H. cinaedi), a Gram-negative spiral-shaped bacterium, is an enterohepatic nonHelicobacter pylori Helicobacter species. We report the first case of H. cinaedi bacteremia with cellulitis after liver transplantation. A 48-year-old male, who had been a dog breeder for 15 years, underwent ABO-incompatible living-donor liver transplantation for hepatitis C virus-induced decompensated cirrhosis using an anti-hepatitis B core antibody-positive graft. The patient was preoperatively administered rituximab and underwent plasma exchange twice to overcome blood type incompatibility. After discharge, he had been doing well with immunosuppression therapy comprising cyclosporine, mycophenolate mofetil, and steroid according to the ABO-incompatible protocol of our institution. However, 7 mo after transplantation, he was admitted to our hospital with a diagnosis of recurrent cellulitis on the left lower extremity, and H. cinaedi was detected by both blood culture and polymerase chain reaction analysis. Antibiotics improved his symptoms, and he was discharged at day 30 after admission. Clinicians should be more aware of H. cinaedi in immunocompromised patients, such as ABO-incompatible transplant recipients. | Kohei Mishima Hideaki Obara Kayoko Sugita Masahiro Shinoda Minoru Kitago Yuta Abe Taizo Hibi Hiroshi Yagi Kentaro Matsubara Takehiko Mori Yaoko Takano Hiroshi Fujiwara Osamu Itano Naoki Hasegawa Satoshi Iwata Yuko Kitagawa | 2015 | World Journal of Gastroenterology2015，21，25： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员